SCHEMBL2807366

SCHEMBL2807366

CC(N[C@H](C)C(=O)O)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
SLC7A5 Q01650 1/20 0.38
MME P08473 2/20 0.38
RAB9A P51151 1/20 0.38
ACE P12821 1/20 0.38
CPA1 P15085 1/20 0.38
ACE2 Q9BYF1 1/20 0.38
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
FOLH1 Q04609 2/20 0.33
NAALAD2 Q9Y3Q0 2/20 0.33
RNPEP Q9H4A4 1/20 0.33
CYP1A2 P05177 1/20 0.33
ADAMTS4 O75173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL88208 1.00 TP53 (0.47) TP53SLC7A5MMERAB9AACE
SCHEMBL3808901 1.00 TP53 (0.47) TP53SLC7A5MMERAB9AACE
SCHEMBL4572684 1.00 TP53 (0.47) TP53SLC7A5MMERAB9AACE
SCHEMBL4572680 1.00 TP53 (0.47) TP53SLC7A5MMERAB9AACE
SCHEMBL109878 1.00 TP53 (0.47) TP53SLC7A5MMERAB9AACE
Alanine SCHEMBL7753217 0.88 SLC7A5 (0.43) TP53SLC7A5MMERAB9AACE
Ethylene Glycol SCHEMBL14742452 0.88 TP53 (0.38) TP53SLC7A5MMEACECPA1
SCHEMBL3978169 0.87 TP53 (0.42) TP53SLC7A5MMERAB9AACE
SCHEMBL4621286 0.87
SCHEMBL4622077 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
EP-2207525-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'Oréal (FR) 2010-07-21 EP claimed
EP-2205201-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'Oreal (FR) 2010-07-14 EP claimed
WO-2009053594-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO claimed
WO-2009053584-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO claimed
WO-2009053587-A2 COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO claimed
EP-4204100-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE L'OREAL (FR) 2023-07-05 EP disclosed
US-11559474-B2 Hair lightening compositions and methods of use L'OREAL (FR) 2023-01-24 US disclosed
WO-2022047081-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE HENRY DEREK (US) 2022-03-03 WO disclosed
EP-2207525-B1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'ORÉAL (FR) 2017-02-22 EP disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
EP-2205201-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'Oreal (FR) 2010-07-14 EP disclosed
WO-2009053594-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO disclosed
WO-2009053584-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO disclosed
WO-2009053587-A2 COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2009-04-30 WO disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed
EP-2008647-A1 Cosmetic or pharmaceutical composition comprising a condensation polymer, cosmetic treatment method, condensation polymer and preparation method L'Oreal (FR) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 TP53 964/4885SLC7A5 3923/4885MME 4682/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB TP53 1857/4885SLC7A5 4680/4885MME 3908/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA TP53 1009/4885SLC7A5 2033/4885MME 4814/4885
US-11559474-B2 Hair lightening compositions and methods of use TYR, ALAD, CYBA TP53 3027/4885SLC7A5 701/4885MME 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.